Hepatic impairment
Clinical trials for Hepatic impairment explained in plain language.
Never miss a new study
Get alerted when new Hepatic impairment trials appear
Sign up with your email to follow new studies for Hepatic impairment, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a damaged liver change how a new drug works?
Knowledge-focused Not yet recruitingThis early-stage trial is investigating how a single oral dose of the experimental drug AZD4144 is processed by the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. The goal is to measure how liver function affects drug levels in the …
Matched conditions: HEPATIC IMPAIRMENT
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
New obesity drug tested in people with liver problems
Knowledge-focused Not yet recruitingThis early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…
Matched conditions: HEPATIC IMPAIRMENT
Phase 1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Liver function may change how lung cancer drug works
Knowledge-focused Not yet recruitingThis early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.
Matched conditions: HEPATIC IMPAIRMENT
Phase 1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Liver function and drug levels: a closer look at GS1-144
Knowledge-focused Not yet recruitingThis early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.
Matched conditions: HEPATIC IMPAIRMENT
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Liver function may change how anxiety drug works
Knowledge-focused Not yet recruitingThis early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The …
Matched conditions: HEPATIC IMPAIRMENT
Phase 1 • Sponsor: Beijing Union Pharmaceutical Factory Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC